It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**
Below is a list of phase III clinical trials that are currently enrolling patients as recorded at the close of 2021. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medicine before it is approved for use by all patients with the indicated disease.
Many of these are trials of a “novel/investigational agent” – meaning it is the first time a particular treatment is being tried for brain tumor patients. There are also a number of trials with therapies already in use for some brain tumor patients, for which researchers are evaluating these existing treatments in different combinations, different dosing regimens, and/or specific subgroups of patients.
Phase III Clinical Trials with Novel/Investigational Agents
Phase III Clinical Trials with Prior/Known Agents
*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder, where you can search potential opportunities for enrollment based on criteria specific to you.
**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing firstname.lastname@example.org. Our patient navigation team has years of experience working closely with brain tumor patients and families.
> Learn more
TAGGED WITH: biotech, biotechnology, brain cancer, brain tumor, Cancer, Oligodendroglioma, biopharma, GBM, glioblastoma, chemotherapy, childhood cancer, high-grade glioma, pediatric brain tumor, low-grade glioma, Medulloblastoma, brain tumor community, astrocytoma, Treatment, meningioma, precision medicine, DIPG, glioma, immunotherapy, Clinical trials, Ependymoma